Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06567795 · ClinicalTrials.gov registry record

PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG

A clinical trial of Diabetes Mellitus, Type 2 and Cardiovascular Diseases, sponsored by Aventusoft.

Recruiting
Registry status
189
Enrollment target
1
Study location

NCT06567795 is a study of Diabetes Mellitus, Type 2 and Cardiovascular Diseases that is actively recruiting participants, run by Aventusoft. The registered enrollment target is 189 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06567795, a study of Diabetes Mellitus, Type 2 and Cardiovascular Diseases, is actively recruiting participants, sponsored by Aventusoft.

RECRUITING
Registry status
189 participants
Enrollment target
1
Study location

Study Summary

To evaluate the proportion of diabetic mellitus patients with CV events as measured by HEMOTAG.

Interventions

  • DEVICE Hemotag

Study Locations (1)

Florida

  • Metabolic Research Institute, Inc - West Palm Beach

Trial Details

FieldValue
Enrollment Target 189 participants
Start Date 2024-03-14
Est. Completion 2027-03-18

Sponsor

Aventusoft

2 total trials

What the Registry Record Tells You About NCT06567795

The ClinicalTrials.gov registry entry for NCT06567795 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 189 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (96% lower). The listed sponsor is Aventusoft, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Hemotag is the first listed.

NCT06567795 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06567795 about?

NCT06567795 is a clinical study titled "PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG". To evaluate the proportion of diabetic mellitus patients with CV events as measured by HEMOTAG.

What is the current status of trial NCT06567795?

This trial is currently recruiting. The enrollment target is 189 participants. The study started on 2024-03-14. Estimated completion is 2027-03-18.

What conditions does trial NCT06567795 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Cardiovascular Diseases, Coronary Artery Disease, Peripheral Artery Disease, Cerebrovascular Disease.

What interventions are being tested in trial NCT06567795?

The interventions under investigation include: Hemotag (DEVICE).

Who is sponsoring clinical trial NCT06567795?

This trial is sponsored by Aventusoft, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06567795 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.